Mary Philip

Vanderbilt University — United States

Medicine · Health Sciences

27h-index8.5kcitations132works0.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(41), CAR-T cell therapy research(40), Immune Cell Function and Interaction(32), Infective Endocarditis Diagnosis and Management(24), Immunotherapy and Immune Responses(23)

Publications132 total

Pre-division TCF1 drop determines long-term CD8 T cell fates
2025Open Access
MDR1 promotes CD8 T cell persistence in tumors and protects against cytotoxic chemotherapy
2025Open Access
Vaccination generates functional progenitor tumor-specific CD8 T cells and long-term tumor control
Journal for ImmunoTherapy of Cancer·2024· 1 citedOpen Access
Dysfunctional CD8 T cells in tumors are addicted to antigen
The Journal of Immunology·2024
Atrioventricular conduction disorders in aortic valve infective endocarditis
Archives of cardiovascular diseases·2024· 4 citedOpen Access
P12.11 RECQL4 promotes immune evasion and limits response to anti-PD-1 therapy and survival in melanoma patients
Poster presentations·2024Open Access
Vaccination generates functional progenitor tumor-specific CD8 T cells and long-term tumor control
2024Open Access
ETO dans l’endocardite infectieuse
Elsevier eBooks·2024
Characteristics and prognosis of isolated aortic valve infective endocarditis in patients with bicuspid aortic valves: a propensity matched study
Frontiers in Cardiovascular Medicine·2023· 4 citedOpen Access
Figure S5 from Tumor-Reactive CD8<sup>+</sup> T Cells Enter a TCF1<sup>+</sup>PD-1<sup>−</sup> Dysfunctional State
2023Open Access
Figure S6 from Tumor-Reactive CD8<sup>+</sup> T Cells Enter a TCF1<sup>+</sup>PD-1<sup>−</sup> Dysfunctional State
2023Open Access
Data from Tumor-Reactive CD8<sup>+</sup> T Cells Enter a TCF1<sup>+</sup>PD-1<sup>−</sup> Dysfunctional State
2023Open Access
Figure S3 from Tumor-Reactive CD8<sup>+</sup> T Cells Enter a TCF1<sup>+</sup>PD-1<sup>−</sup> Dysfunctional State
2023Open Access
Figure S1 from Tumor-Reactive CD8<sup>+</sup> T Cells Enter a TCF1<sup>+</sup>PD-1<sup>−</sup> Dysfunctional State
2023Open Access
Abstract PR06: Hallmarks of CD8 T cell dysfunction are established within hours of tumor antigen encounter prior to cell division
Cancer Immunology Research·2023
Figure S3 from Tumor-Reactive CD8<sup>+</sup> T Cells Enter a TCF1<sup>+</sup>PD-1<sup>−</sup> Dysfunctional State
2023Open Access
Supplementary Tables from Tumor-Reactive CD8<sup>+</sup> T Cells Enter a TCF1<sup>+</sup>PD-1<sup>−</sup> Dysfunctional State
2023Open Access
Figure S1 from Tumor-Reactive CD8<sup>+</sup> T Cells Enter a TCF1<sup>+</sup>PD-1<sup>−</sup> Dysfunctional State
2023Open Access
Figure S7 from Tumor-Reactive CD8<sup>+</sup> T Cells Enter a TCF1<sup>+</sup>PD-1<sup>−</sup> Dysfunctional State
2023Open Access
Data from Tumor-Reactive CD8<sup>+</sup> T Cells Enter a TCF1<sup>+</sup>PD-1<sup>−</sup> Dysfunctional State
2023Open Access
page 1 of 7Next →

Frequent Co-authors

Andrea Schietinger(12), Gilbert Habib(12), Florent Arregle(10), Frédérique Gouriet(10), Edward N. Libby(10), Ajay K. Gopal(10), Hélène Martel(9), Ryan D. Cassaday(9), Hans Schreiber(8), Sandrine Hubert(8), Alberto Ribéri(8), Didier Raoult(8), Andrei R. Shustov(8), Oliver W. Press(8), Laurence Camoin‐Jau(7), Michel Drancourt(7), Stephen D. Smith(7), Brian G. Till(7), Jean Paul Casalta(6), Hubert Lépidi(6)